More patients had delayed disease progression with TECENTRIQ with COTELLIC® (cobimetinib) and ZELBORAF® (vemurafenib)
TECENTRIQ was studied with COTELLIC and ZELBORAF in a clinical trial that included 514 patients with BRAF V600+ unresectable or metastatic melanoma who were previously untreated.
Median progression-free survival (PFS)*
Patients receiving TECENTRIQ with COTELLIC and ZELBORAF were 22% less likely to experience disease progression or death compared to those receiving COTELLIC and ZELBORAF alone.
*Median PFS = The length of time from the start of treatment in a trial that half the patients lived without their tumors growing or spreading.
TECENTRIQ may not work for everyone.
Safety information you should be aware of
Possible serious side effects with TECENTRIQ include, but are not limited to, lung problems, intestinal problems, liver problems, hormone gland problems, kidney problems, skin problems, problems in other organs, severe infusion reactions, and complications, including graft-versus-host disease (GVHD), in people who have received a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic).
The percentage of patients who responded to TECENTRIQ with COTELLIC and ZELBORAF was similar to those who were given COTELLIC and ZELBORAF (66% compared with 65%)†
†Response means the cancer was reduced or could no longer be detected on a scan.
Patients responded to treatment longer on TECENTRIQ with COTELLIC and ZELBORAF than to COTELLIC and ZELBORAF alone
Median duration of response (DoR)‡
‡Median DoR = The amount of time that half the people in this trial had an initial response to treatment until the cancer grew or spread.